Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abeona Therapeutics (ABEO) Asset Writedowns and Impairment (2022)

Abeona Therapeutics (ABEO) has 1 years of Asset Writedowns and Impairment data on record, last reported at -$445000.0 in Q3 2022.

  • For Q3 2022, Asset Writedowns and Impairment changed N/A year-over-year to -$445000.0; the TTM value through Dec 2023 reached -$445000.0, down 132.84%, while the annual FY2023 figure was -$1.1 million, 178.6% down from the prior year.
  • Asset Writedowns and Impairment reached -$445000.0 in Q3 2022 per ABEO's latest filing, down from $445000.0 in the prior quarter.
  • Across five years, Asset Writedowns and Impairment topped out at $1.4 million in Q1 2022 and bottomed at -$445000.0 in Q3 2022.